(Reuters) - Merck & Co ( MRK ) is nearing a $1.3 billion cash deal to buy ophthalmology biotechnology company Eyebiotech in an agreement that could see an additional $1.7 billion in milestone payments, the Wall Street Journal reported on Tuesday.
(Reporting by Kanjyik Ghosh; Editing by Subhranshu Sahu)